Gilead Sciences Maintains 11-Year Dividend Growth Streak Supported by HIV and Oncology Revenue
Gilead Sciences (GILD) has demonstrated strong financial resilience, marking its 11th consecutive year of dividend increases. The company recently raised its quarterly dividend by 3.8% to $0.82 per share, supported by a low payout ratio of 29.8%. This stability is primarily driven by the company's dominant HIV franchise, which saw an 18% increase in sales during the third quarter. Beyond HIV treatments, Gilead is successfully diversifying its portfolio into oncology and anti-inflammatory therapies. The cancer drug Trodelvy reported a significant 42% year-over-year sales increase, reaching $506 million in Q3. With plans to invest $32 billion in research through 2030 and robust free cash flow growth of 68% over nine months, the company is well-positioned for continued expansion.
Topics: dividend increase free cash flow HIV therapies oncology quarterly revenue